08.01.22 Stem Cell Therapy for Orthopedic Indications (Including Allograft Bone Products used with Stem Cells)

Original Effective Date: June 2014

Review Date: March 2025

Revised: March 2025

DISCLAIMER/INSTRUCTIONS FOR USE

This policy contains information which is clinical in nature. The policy is not medical advice. The information in this policy is used by Wellmark to make determinations whether medical treatment is covered under the terms of a Wellmark member's health benefit plan. Physicians and other health care providers are responsible for medical advice and treatment. If you have specific health care needs, you should consult an appropriate health care professional. If you would like to request an accessible version of this document, please contact customer service at 800-524-9242.

Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations, or exceptions may apply. Benefits may vary based on contract, and individual member benefits must be verified. Wellmark determines medical necessity only if the benefit exists and no contract exclusions are applicable. This medical policy may not apply to FEP. Benefits are determined by the Federal Employee Program.

This Medical Policy document describes the status of medical technology at the time the document was developed. Since that time, new technology may have emerged, or new medical literature may have been published. This Medical Policy will be reviewed regularly and updated as scientific and medical literature becomes available; therefore, policies are subject to change without notice.

Related Policies:

- 02.01,32 Platelet-Rich Plasma and Autologous Protein Solution for Orthopedic Applications
- 02.01.18 Prolotherapy

Summary

Description

Note: *This evidence review does not address stem cell therapy used for disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment, or hematopoietic stem cell transplantation. Refer medical policy 07.03.11 Hematopoietic Stem Cell Transplantation (Bone Marrow Transplant) Autologous and Allogeneic**

Mesenchymal stem cells (MSCs) have the capability to differentiate into a variety of tissue types, including various musculoskeletal tissues. Potential uses of MSCs for orthopedic applications include treatment of damaged bone, cartilage, ligaments, tendons, and intervertebral discs.

Summary of Evidence

For individuals who have cartilage defects, meniscal defects, joint fusion procedures, or osteonecrosis who receive stem cell therapy, the evidence includes randomized controlled trials (RCTs) and nonrandomized comparative trials. Relevant outcomes are symptoms, morbid events, functional outcomes, quality of life (QOL), and treatment-related morbidity. Use of MSCs for orthopedic conditions is an active area of research. Despite continued research into the methods of harvesting and delivering treatment, there are uncertainties regarding the optimal source of cells and the delivery method. Studies have included MSCs from bone marrow, adipose tissue, and peripheral blood. Overall, the quality of evidence is low and there is a possibility of publication bias. The strongest evidence to date is on autologous MSCs expanded from bone marrow, which includes several phase 1/2 RCTs and a phase 3 RCT (which also evaluated other cell therapies). The phase 3 trial did not indicate significant improvements with the cell therapy modalities relative to active-control intra-articular corticosteroid injections for patients with knee osteoarthritis after 12 months of follow-up. Another recent phase 3 RCT evaluated autologous MSCs expanded from abdominal adipose tissue for treatment of knee osteoarthritis; this trial indicated autologous adipose-derived MSCs were more effective than matching placebo injections in improving pain, function, and other patient-reported outcomes after 6 months of follow-up. These phase 3 trials' mixed findings may be related to differences in the cell therapy modalities used, baseline cohort characteristics, and/or the use of an active vs placebo control. Alternative methods of obtaining MSCs have been reported in a smaller number of trials and with mixed results. Additional study in a larger sample of patients with longer follow-up would be needed to evaluate the long-term efficacy and safety of these procedures. Also, expanded MSCs for orthopedic applications are not U.S. Food and Drug Administration approved (concentrated autologous MSCs do not require agency approval). Overall, there is a lack of evidence that clinical outcomes are improved. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Additional Information

Not applicable.

OBJECTIVE

The objective of this evidence review is to evaluate whether the use of mesenchymal stem cells (MSCs) in conjunction with interventions for orthopedic conditions improves the net health outcome.

PRIOR APPROVAL

- Prior approval is **ONLY** required for codes 38240 and 38241 when used for Hematopoietic Stem Cell Transplantation Autologous and Allogeneic* see 07.01.11

- When these codes and all other codes in this medical policy are used for stem cell therapy they do **NOT** require prior approval.

POLICY

Note: *This evidence review does not address stem cell therapy used for disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment, or hematopoietic stem cell transplantation. Refer medical policy 07.03.11 Hematopoietic Stem Cell Transplantation (Bone Marrow Transplant) Autologous and Allogeneic**

Mesenchymal stem cell (MSC) therapy is considered **investigational** for all orthopedic applications, including use in repair or regeneration of musculoskeletal tissue. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Allograft bone products containing viable stem cells, including but not limited to demineralized bone matrix (DMB) with stem cells is considered **investigational** for all orthopedic applications. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Allograft or synthetic bone graft substitutes that must be combined with autologous blood or bone marrow are considered **investigational** for all orthopedic applications. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

POLICY GUIDELINES

Note: *See Regulatory Status Tables 1 and 2 for examples of investigational products. This policy does not address unprocessed allograft bone or products that do not require mixing with stem cells.*

Coding

See the Codes table for details.

BACKGROUND

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are multipotent cells (also called multipotent stromal cells) that can differentiate into various tissues including organs, trabecular bone, tendon, articular cartilage, ligaments, muscle, and fat. MSCs are associated with the blood vessels within the bone marrow, synovium, fat, and muscle, where they can be mobilized for endogenous repair as occurs with the healing of bone fractures. Tissues such as cartilage, tendon, ligaments, and vertebral discs show limited capacity for endogenous repair because of the limited presence of the triad of functional tissue components: vasculature, nerves, and lymphatics. Orthobiologics is a term introduced to describe interventions using cells and biomaterials to support healing and repair. Cell therapy is the application of MSCs directly to a musculoskeletal site. Tissue engineering techniques use MSCs and/or bioactive molecules such as

growth factors and scaffold combinations to improve the efficiency of repair or regeneration of damaged musculoskeletal tissues.

Bone marrow aspirate is considered the most accessible source and, thus, the most common place to isolate MSCs for the treatment of musculoskeletal disease. However, harvesting MSCs from bone marrow requires a procedure that may result in donor-site morbidity. Also, the number of MSCs in bone marrow is low, and the number and differentiation capacity of bone marrow derived MSCs decreases with age, limiting their efficiency when isolated from older patients.

In vivo, the fate of stem cells is regulated by signals in the local 3-dimensional microenvironment from the extracellular matrix and neighboring cells. It is believed the success of tissue engineering with MSCs will also require an appropriate 3-dimensional scaffold or matrix, culture conditions for tissue-specific induction, and implantation techniques that provide appropriate biomechanical forces and mechanical stimulation. The ability to induce cell division and differentiation without adverse effects, such as the formation of neoplasms, remains a significant concern. Given that each tissue type requires different culture conditions, induction factors (signaling proteins, cytokines, growth factors), and implantation techniques, each preparation must be individually examined.

Regulatory Status

The U.S. Food and Drug Administration (FDA) regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation, Title 21, parts 1270 and 1271. MSCs are included in these regulations.

The regulatory status of the stem cell or stem cell- containing products addressed in this review is summarized below.

Concentrated autologous MSCs do not require approval by the FDA. No products using engineered or expanded MSCs have been approved by the FDA for orthopedic applications.

The following products are examples of commercialized demineralized bone matrix (DBM) products. They are marketed as containing viable stem cells. In some instances, manufacturers have received communications and inquiries from the FDA related to the appropriateness of their marketing products that are dependent on living cells for their function. The following descriptions are from the product literature.

- AlloStem® (AlloSource) is a partially demineralized allograft bone seeded with adipose-derived MSCs.
- Map3® (RTI Surgical) contains cortical cancellous bone chips, DBM, and cryopreserved multipotent adult progenitor cells (MAPC®).
- Osteocel Plus® (NuVasive) is a DBM combined with viable MSCs isolated from allogeneic bone marrow.
- Trinity Evolution Matrix™ (Orthofix) is a DBM combined with viable MSCs isolated from allogeneic bone marrow.
- Other products contain DBM alone and are designed to be mixed with bone marrow aspirate:
    - Fusion Flex™ (Wright Medical) is a dehydrated moldable DBM scaffold (strips and cubes) that will absorb autologous bone marrow aspirate;
    - Ignite® (Wright Medical) is an injectable graft with DBM that can be combined with autologous bone marrow aspirate.

A number of DBM combination products have been cleared for marketing by the FDA through the 510(k) process. FDA product code: MQV.

Tables 1 and 2 represent samples of these products, differentiated by whether they must be mixed with autologous MSCs.

Table 1. Examples of Demineralized Bone Matrix Products Cleared by FDA that Do Not Require Mixing with Autologous MSCs

Product	Matrix Type	Manufacturer or Sponsor	Date Cleared	510(k) No.
Vitoss® Bioactive Foam Bone Graft Substitute	Type I bovine collagen	Stryker	Nov 2008	K083033
NanOss BVF-E	Nanocrystalline hydroxyapatite	Pioneer Surgical	Aug 2008	K081558
OrthoBlast® II Demineralized bone matrix putty and paste	Human (mixed allograft donor-derived) cancellous bone chips	SeaSpine	Sep 2007	K070751
DBX® Demineralized bone matrix putty, paste and mix	Processed human (single allograft donor-derived) bone and sodium hyaluronate	Musculoskeletal Transplant Foundation	Dec 2006	K053218
Formagraft™ Collagen Bone Graft Matrix	Bovine fibrillary collagen	R and L Medical	May 2005	K050789
DynaGraft® II Gel and Putty	Processed human (mixed allograft donor-derived) bone particles	IsoTis Orthobiologics	Mar 2005	K040419

FDA: U.S. Food and Drug Administration; MSCs: mesenchymal stem cells.

Table 2. Examples of Demineralized Bone Matrix Products Cleared by FDA that Require Mixing with Autologous MCSs

Product	Matrix Type	Manufacturer or Sponsor	Date Cleared	510(k) No.
CopiOs® Bone Void Filler (sponge and powder disc)	Type I bovine dermal collagen	Kensey Nash	May 2007	K071237
Integra MOZAIK™ Osteoconductive Scaffold-Putty	Collagen matrix with tricalcium phosphate granules	IsoTis OrthoBiologics	Dec 2006	K062353

FDA: U.S. Food and Drug Administration; MSCs: mesenchymal stem cells.

In 2020, the FDA updated their guidance on "Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use."

Human cells, tissues, and cellular and tissue-based products (HCT/P) are defined as human cells or tissues that are intended for implantation, transplantation, infusion, or transfer into a human recipient. If an HCT/P does not meet the criteria below and does not qualify for any of the stated exceptions, the HCT/P will be regulated as a drug, device, and/or biological product and applicable regulations and premarket review will be required.

An HCT/P is regulated solely under section 361 of the PHS Act and 21 CFR Part 1271 if it meets all of the following criteria:

"1) The HCT/P is minimally manipulated.

2) The HCT/P is intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.

3) The manufacture of the HCT/P does not involve the combination of the cells or tissues with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent, provided that the addition of water, crystalloids, or the sterilizing, preserving, or storage agent does not raise new clinical safety concerns with respect to the HCT/P; and

4) Either:

i) The HCT/P does not have a systemic effect and is not dependent upon the metabolic activity of living cells for its primary function; or

ii) The HCT/P has a systemic effect or is dependent upon the metabolic activity of living cells for its primary function, and: a) Is for autologous use; b) Is for allogeneic use in a first-degree or second-degree blood relative; or c) Is for reproductive use."

The FDA does not consider the use of stem cells for orthopedic procedures to be homologous use.

RATIONALE

This evidence review was created in June 2014 and has been updated regularly with searches of the PubMed database. The most recent literature update was performed through March 2025.

Evidence reviews assess the clinical evidence to determine whether the use of technology improves the net health outcome. Broadly defined, health outcomes are the length of life, quality of life (QOL), and ability to function, including benefits and harms. Every clinical condition has specific outcomes that are important to individuals and managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, 2 domains are examined: the relevance, and quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The RCT is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. Randomized controlled trials are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

Cartilage Defects

Clinical Context and Therapy Purpose

The purpose of stem cell therapy is to provide a treatment option that is an alternative to or an improvement on existing therapies in individuals with osteoarthritis (OA) or focal cartilage defects.

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is individuals with OA or focal cartilage defects.

Interventions

The therapy being considered is treatment with MSCs.

Comparators

Comparators of interest include conservative management with medication or hyaluronic acid (HA) injection, microfracture, and autologous chondrocyte implantation.

Outcomes

The general outcomes of interest are symptoms, morbid events, functional outcomes, QOL, and treatment-related morbidity (TRM). Specific scales may include the:

- Knee Injury and Osteoarthritis Outcome Score (KOOS; 5 subscales with 0-100 scale),
- Lysolm Knee Scale (LKS) score (0-100 scale),
- Tegner Activity Score (TAS); a visual analog scale (VAS) for pain (0-100 mm or 0-10 cm scale),
- Western Ontario and McMaster Universities Arthritis Index (WOMAC) which has 3 sub scores: pain, which includes 5 items; stiffness, with 2 items; and physical function, with 17 items.
- WOMAC response criteria is an improvement of 20% in at least 2 items together with an improvement of 10 points in the overall scale.
- Cartilage is evaluated with the Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART, 0-100 points, where higher scores indicate better cartilage repair).
- Follow-up over months to years is of interest for relevant outcomes.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Review of Evidence

Systematic Reviews

A systematic review and meta-analysis by Borakati et al (2017) included 15 comparative studies (N=582) on the use of MSCs to treat OA or focal osteochondral lesions. The studies (13 published and 2 unpublished data) included 5 RCTs, 1 case-control, and 9 cohort studies. A majority of the studies were conducted in Asia, and the source of the MSCs varied (bone marrow, blood, amniotic fluid, adipose

tissue). The largest trial had only 56 participants, giving low statistical power for the individual studies. The overall quality of the evidence was considered low, with 3 studies rated as "satisfactory" and the rest rated "poor" on the Jadad scale. Pain assessment results were noted for each of the controlled studies, resulting in a pooled standardized mean difference of -1.27 (95% confidence interval [CI], -1.95 to -0.58) in favor of the group treated with MSCs. Reviewers reported a Z-statistic effect size of 3.62, again in favor of the groups treated with MSCs (p<.001); although there was high heterogeneity across controlled studies (I^2=92%). There was also suggestion of publication bias; the investigators found 79 trials on clinicaltrials.gov, of which only 3 were listed as 'complete with results,' many trials had been inactive for several years, and 9 had 'unknown' status.

A systematic review and meta-analysis by Maheshwer et al (2020) identified 25 studies with 439 participants that used MSCs for treatment of OA. Although 13 studies were considered level I RCTs by the authors (range of 7 to 40 participants), low quality RCTs would normally be downgraded to level II. Meta-analysis suggested improvement in self-reported function, but only in patients who underwent concomitant surgery, and there was no significant improvement in pain. Few studies reported on cartilage quality. Most of the studies were rated as poor or fair quality. Conclusions are limited due to substantial variability in MSC source, preparation, and concentration in the current literature.

Wiggers et al (2021) conducted a systematic review of RCTs evaluating autologous mesenchymal stem cell therapy on patient-reported outcome measures and disease severity. Fourteen RCTs were identified in searches conducted through December 2020. Meta-analysis was precluded because most of the original trial data were not available for pooling and due to heterogeneity across studies. A total of 408 patients with knee osteoarthritis received MSC therapy derived from bone marrow, adipose tissue, or activated peripheral blood. After 1 year, 19 of 26 (73%) clinical outcome measures improved with MSCs compared with control. In the MSC group, patients improved by 1.8 to 4.4 points on the Visual Analogue Scale (0 to 10) and 18 to 32 points on the Knee Osteoarthritis Outcome Score (0 to 100). Four studies showed better disease severity on imaging after MSC compared with control at 1 year. Although the reviewers found a positive effect of autologous MSC therapy compared with control treatments, the certainty of the evidence was rated low to very low due to high risk of bias in the included studies (e.g., 10 of 14 RCTs were at high risk of bias on all outcomes) and high heterogeneity in the source, method of preparation, and dosage of injected stem cells in included RCTs.

A more focused systematic review and meta-analysis of 6 RCTs (N=203) that evaluated cultured MSCs for OA was reported by Kim et al (2020). Four of the studies used bone marrow-derived MSCs, 1 used adipose-derived cells, and the other cultured placental cells. Only 2 of the 6 studies were rated as low risk of bias. Pain outcomes measured with VAS and WOMAC pain scales were improved at 6 to 12 months, but there was no significant improvement in measures of WOMAC function or cartilage measured by magnetic resonance imaging.

Jin et al (2022) also conducted a more focused systematic review and meta-analysis of 6 RCTs (N=452) that evaluated intra-articular MSC injection in patients undergoing high tibial osteotomy (HTO). Results demonstrated that there were no significant differences in the International Knee Documentation Committee (IKDC) score and KOOS Pain and Symptoms subscales in patients who underwent HTO with or without the MSC injection. However, patients who received MSC injection had significantly greater improvements in Lysholm scores (mean difference, 2.55; 95% CI, 0.70 to 4.40; p=.007), and greater proportions of International Cartilage Regeneration and Joint Preservation Society (ICRS) grade 1 (p=.03) and grade 2 (p=.02) cartilage repair in the medial femoral condyle and grade 2 cartilage repair in the tibial plateau (p=.04).

Giorgino et al (2024) conducted a systematic review evaluating intra-articular MSC injections for the management of hip OA. The review included 10 studies (N=316) with diverse designs and outcomes,

examining pain relief, functional improvement, and cartilage repair through various imaging, pain score, and functional improvement scoring systems like WOMAC, VAS, and hip outcome score–activities of daily living (HOS-ADL). Results showed favorable outcomes regarding pain relief and functional enhancement, with minimal adverse events such as transient joint pain and hematomas. Despite the promising outcomes, the authors highlighted limitations such as small sample sizes, lack of control groups, and heterogeneity in MSC sources and treatment protocols. Further large-scale controlled trials with standardized methodologies are recommended to optimize MSC therapies for hip OA.

The source of MSCs may have an impact on outcomes, but this is not well-understood, and the available literature uses multiple sources of MSCs. Because of the uncertainty over whether these products are equivalent, the evidence is grouped by the source of MSC.

Mesenchymal Stem Cells Expanded from Bone Marrow

Autologous Bone Marrow

Wakitani et al (2002) first reported on the use of expanded MSCs for repair of cartilage defects. Cells from bone marrow aspirate of 12 patients with OA knees were culture-expanded, embedded in collagen gel, transplanted into the articular cartilage defect, and covered with autologous periosteum at the time of HTO. Clinical improvement did not differ between the experimental group and a group of 12 control patients who underwent HTO alone. Wakitani et al (2007) have since published several cases of patients treated for isolated cartilage defects, with clinical improvement reported at up to 27 months. However, most of the defects appear to have been filled with fibrocartilage. A report from Wakitani et al (2011) was a follow-up safety study of 31 of the 41 patients (3 patients had died, 5 had undergone total knee arthroplasty) who had received MSCs for articular cartilage repair in their clinics between 1998 and 2008 At a mean of 75 months (range, 5-137 months) since the index procedure, no tumors or infections were identified. Functional outcomes were not reported.

A publication from Centeno et al (2010) of Regenerative Sciences in the United States described the use of percutaneously injected culture expanded MSCs obtained from the iliac spine in 226 patients. Following harvesting, cells were cultured with autologous platelet lysate and reinjected under fluoroscopic guidance into peripheral joints (n=213) or intervertebral discs (n=13). Culture-expanded MSCs requires approval by the U.S. Food and Drug Administration (FDA) and is no longer offered in the United States.

The largest study included in the systematic review by Borakati et al (2017) was by Wong et al (2013), who reported on an RCT of cultured MSCs in 56 patients with OA who underwent medial opening wedge HTO and microfracture of a cartilage lesion (See Tables 3 and 4). Patients received an intra-articular injection of MSCs suspended in HA, or for controls, intra-articular injection of HA alone. The primary outcome was the IKDC score at 6 months, 1 year, and 2 years. Secondary outcomes were the TAS and LKS scores through 2 years and the MOCART scoring system by magnetic resonance imaging (MRI) at 1 year. All patients completed the 2-year follow-up. After adjusting for age, baseline scores, and time of evaluation, the group treated with MSCs showed significantly better scores on the IKDC (mean difference, 7.65 on 0-100 scale; p=.001), LKS (mean difference, 7.61 on 0-100 scale; p=.02), and TAS (mean difference, 0.64 on a 0-10 scale; p=.02) scores. The clinical significance of these differences is uncertain. Blinded analysis of MRI results found higher MOCART scores in the MSC group. The group treated with MSCs had a higher proportion of patients who had complete cartilage coverage of their lesions (32% vs. 0%), greater than 50% cartilage cover (36% vs. 14%), and complete integration of the regenerated cartilage (61% vs. 14%).

Emadedin et al (2018) reported a triple-blind, placebo-controlled, phase 1/2 trial of expanded MSCs in 47 patients with OA of the knee. Compared to the placebo group, the MSC group showed statistically significant improvements in WOMAC pain and function subscales but not VAS. The WOMAC stiffness subscale improved to a similar extent in the 2 groups. Minimum Clinically Important Improvement and Patient Acceptable Symptom State were not significantly different between the 2 groups. Study limitations included the short duration of follow-up, statistical analysis, and lack of information regarding use of analgesic medications (see Tables 5 and 6).

Another phase 1/2 RCT of expanded MSCs was reported by Lamo-Espinosa et al (2016, 2018) in 30 patients with OA of the knee. Two doses of MSCs ($10x10^6$, $100x10^6$) were administered with HA and compared to injection of HA alone. VAS scores were significantly decreased in both MSC groups compared to baseline throughout the 12 months of follow-up, while the decrease in VAS in the control group was not statistically significant. Similarly, total WOMAC scores were statistically decreased only in the high dose group at 12 months. Four-year follow-up was available for 27 of the 30 participants. Two patients in the control group and 1 patient in the low dose group had undergone total knee arthroplasty. VAS scores were higher than at baseline in the HA control group but remained low in the 2 MSC groups. WOMAC scores at the long-term follow-up showed a similar course (see Table 4). Limitations of this study are described in Tables 5 and 6.

Mautner et al (2023) compared multiple autologous and allogeneic cell-based therapies with gold-standard corticosteroid injection in 475 adults with OA of the knee in a single-blind phase 3 RCT (Tables 3 through 6). Patients were randomized to 1 of 2 autologous cell therapies (bone marrow aspirate concentrate [BMAC] or stromal vascular fraction), allogeneic umbilical cord-derived MSCs, or intra-articular corticosteroid injection; the co-primary endpoints were changes from baseline in VAS and Knee injury and Osteoarthritis Outcome Score pain scores at 12-month follow-up. No significant differences in pain scores were noted in comparisons between corticosteroid injection and any of the cell therapy arms.

Table 3. Summary of Key RCT Characteristics

Study; Trial	Countries	Sites	Dates	Participants	Interventions	
					Active	**Comparator**
Wong et al (2013)	Singapore	1	NR	Patients with OA who underwent HTO and microfracture (N=56)	Microfracture followed by expanded MSCs suspended in HA	Microfracture plus HA alone
Emadedin et al (2018)	Iran	1	2012-2016	Patients who met the ACR clinical and radiological criteria for knee OA (N=47)	40x106 expanded MSCs with serum albumin (n=22)	Placebo (n=25)
Lamo-Espinosa et al (2016, 2018)	Spain	2	2012-2014	Patients who met the ACR clinical and radiological criteria for knee OA (N=30)	One of 2 doses of expanded MSCs with HA 10x106, 100x106	HA alone
Mautner et al (2023)	US	5	2019-2021	Patients with radiographic evidence of knee OA and OA pain despite conservative measures (N=475)	Autologous bone marrow aspirate concentrate (n=118) Autologous stromal vascular fraction (n=119)	Corticosteroid injection (n=120)

					Allogeneic umbilical cord MSCs (n=118)	

ACR: American College of Rheumatology; HA: hyaluronic acid; HTO: high tibial osteotomy; MSC: mesenchymal stem cell; NR: not reported; OA: osteoarthritis; RCT: randomized controlled trial.

Table 4. Summary of Key RCT Results

Study					
Wong et al (2013)	IKDC at 6 mo	IKDC at 2 yr	Tegner Activity Scale at 2 yr	Lysolm Knee Score at 2 yr	MOCART
N	56	56	56	56	56
Diff (95% CI)	7.65 (3.04 to 12.26)		0.64 (0.10 to 1.19)	7.61 (1.44 to 13.79)	19.6 (10.5 to 28.6)
p-Value	.001		.021	.016	<.001
Emadedin et al (2018)[13],	*WOMAC Total*	*WOMAC Pain*	*WOMAC Stiffness*	*WOMAC Function*	*VAS*
N	43	43	43	43	43
MSC (95% CI)	-25.7 (-35.4 to 16)	-35 (-44.9 to 25)	-16.9 (-30.4 to 3.5)	-22.9 (-32.9 to 12.9)	-20.8 (-34.5 to 7.1)
Placebo (95% CI)	5.5 (-2.8 to 13.8)	-12.2 (-18.5 to 5.9)	-13.1 (-20.7 to 5.4)	-9.5 (-21.8 to 2.7)	-15.7 (-33.9 to 2.4)
Diff (95% CI)	-13.5 (-24.3 to 2.7)	-21.8 (-33.8 to 9.9)	-7.4 (-25.4 to 10.5)	-11.3 (-22.1 to 0.4)	-5 (-28.1 to 18)
p-Value	.01	.001	.40	.04	.65
Effect size (95% CI)	0.7 (0.1 to 1.4)	1.1 (0.4 to 1.7)		0.6 (0.03 to 1.2)	
Lamo-Espinosa et al (2016, 2018),	WOMAC Total at 12 mo, median (IQR)	WOMAC Total at 4 yr, median (IQR)	VAS at 4 yr, median (IQR)		
MSC low dose	21.5 (15, 26)	17 (13, 25.5)	2 (2, 5)		
MSC high dose	16.5 (12, 19)	16.5 (8, 23)	3 (3, 4)		
Control	13.5 (8, 33)	27 (17, 30)	7 (6, 7)		
Mautner et al (2023)	100 mm VAS for pain, mean change from baseline to 12 mo	KOOS pain score, mean change from baseline to 12 mo			
Autologous BMAC	-24.3	19.1			
Autologous SVF	-19.4	17.2			
Allogeneic UCT MSCs	-20.1	16.2			
Corticosteroid injection (control)	-20.9	17.7			
p-values	BMAC vs control:.19 SVF vs control:.56 UCT vs control:.76	BMAC vs control:.49 SVF vs control:.82 UCT vs control:.44			

BMAC: bone marrow aspirate concentrate; CI: confidence interval; IKDC: International Knee Documentation Committee score; IQR: interquartile range; KOOS: Knee injury and Osteoarthritis Outcome Score; MOCART; Magnetic Resonance Observation of Cartilage Repair

Tissue; MSC: mesenchymal stem cell; RCT: randomized controlled trial; SEM: standard error of the mean; SVF: stromal vascular fraction; UCT: umbilical cord tissue; VAS: visual analog scale; WOMAC: Western Ontario and McMaster Universities Arthritis Index.

Table 5. Study Relevance Limitations

Study	Population[a]	Intervention[b]	Comparator[c]	Outcomes[d]	Follow-Up[e]
Wong et al (2013)	4. The population was restricted to patients younger than 55	4. The intervention included microfracture with/without stem cells			
Emadedin et al (2018)			2. Did not use an active control and use of analgesics was not reported	1. Evaluation of cartilage was not performed.	1, 2. Follow-up was reported out to 6 mo.
Lamo-Espinosa et al (2016, 2018)				1. Evaluation of cartilage was not performed.	
Mautner et al (2023)					

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.
[a] Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4, Enrolled populations do not reflect relevant diversity; 5. Other.
[b] Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest (e.g., proposed as an adjunct but not tested as such); 5: Other.
[c] Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively; 5. Other.
[d] Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. Incomplete reporting of harms; 4. Not establish and validated measurements; 5. Clinically significant difference not prespecified; 6. Clinically significant difference not supported; 7. Other.
[e] Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms; 3. Other.

Table 6. Study Design and Conduct Limitations

Study	Allocation[a]	Blinding[b]	Selective Reporting[c]	Data Completeness[d]	Power[e]	Statistical[f]
Wong et al (2013)	3. Patients selected from 1 of 2 identical envelopes	1, 2, 3. Not blinded except for evaluation of magnetic resonance imaging				
Emadedin et al (2018)				.	3. Details of power analysis were not reported	1. The authors used non-inferiority compared to placebo and chi-square tests for continuous variables
Lamo-Espinosa et al (2016, 2018)		1, 2, 3. Not blinded			3. Details of power analysis	1. The authors used non-parametric tests for within-group comparisons rather

					were not reported	than tests for repeated measures
Mautner et al (2023)		1,2,3. Single-blind (subjects only)				

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.
[a] Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias; 5. Other.
[b] Blinding key: 1. Participants or study staff not blinded; 2. Outcome assessors not blinded; 3. Outcome assessed by treating physician; 4. Other.
[c] Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication; 4. Other.
[d] Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials); 7. Other.
[e] Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference; 4. Other.
[f] Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated; 5. Other.

Mesenchymal Stem Cells from Allogeneic Bone Marrow

Vega et al (2015) reported on a small phase 1/2 RCT of 30 patients with OA unresponsive to conventional treatments. The MSC-treated group received an intra-articular injection of expanded allogeneic bone marrow MSCs from healthy donors, and the control group received an intra-articular injection of HA. Follow-up using standard outcome measures was performed at 3-, 6-, and 12-months post-injection. In the MSC-treated group, pain scores (VAS and WOMAC) decreased significantly between baseline and the 12-month follow-up, whereas pain scores in the control group did not improve significantly. A significant improvement in cartilage quality in the MSC group was supported by T2 MRI. Not reported was whether the patients or assessors were blinded to treatment.

Mesenchymal Stem Cells from Bone Marrow Aspirate Concentrate

Shapiro et al (2017) reported on the results of a prospective, single-blind, placebo-controlled trial assessing 25 patients with bilateral knee pain from bilateral OA. Patients were randomized to BMAC into 1 knee and to saline placebo into the other. Fifty-two milliliters of bone marrow were aspirated from the iliac crests and concentrated in an automated centrifuge. The resulting BMAC was combined with platelet-poor plasma for injection into the arthritic knee and was compared with a saline injection into the contralateral knee, thereby using each patient as his or her control. Safety outcomes, pain relief, and function as measured by Osteoarthritis Research Society International measures and a VAS score were tracked initially at 1 week, 3 months, and 6 months post-procedure. Study patients experienced a similar relief of pain in both BMAC- and saline-treated arthritic knees.

Mautner et al (2023) compared BMAC with corticosteroid injection in patients with OA in a single-blind RCT. The study is fully described above and in Tables 3 through 6.

Adipose-Derived Mesenchymal Stem Cells

Adipose-derived stem cells are multipotent MSCs that can be harvested from multiple anatomic locations and with greater ease than bone marrow- derived MSCs. The literature on adipose-derived MSCs for articular cartilage repair comes primarily from research groups in Korea. One group appears to have been providing this treatment as an option for patients for a number of years. They compared outcomes of this new add-on treatment with those for patients who only received other cartilage repair procedures.

Hayes Inc Health Technology Assessment February 2022 Autologous Microfragmented Adipose Tissue (MFAT) Injection for Treatment of Osteoarthritis which found the overall quality of evidence to be very low.

The primary limitation related to the evidence is the scarcity of direct comparative evidence. Based on the limited comparative evidence, the evidence is insufficient to inform whether MFAT provides better, worse or equivocal care as any other intervention to sham control.

Koh et al (2014) reported on results of an RCT that evaluated cartilage healing after HTO in 52 patients with OA.[·] Patients were randomized via sealed envelopes to HTO with the application of platelet-rich plasma (PRP) or to HTO with the application of PRP plus MSCs. A total of 44 patients completed second-look arthroscopy and 1- and 2-year clinical follow-ups. The primary outcomes were the KOOS (0-100 scale), the LKS score (0-100 scale), and a VAS for pain (0-100 scale). There were statistically significant differences between PRP only and PRP plus MSC on 2 of 5 KOOS subscales: pain (74 vs. 81.2, p<.001) and symptoms (75.4 vs. 82.8, p=.006), all respectively. There were also statistically significant differences on the final pain score between the PRP only (16.2) and PRP plus MSC groups (10.2; p<.001), but the final LKS score did not differ significantly between the PRP only (80.6) and PRP plus MSC groups (84.7; p=.36). Articular cartilage healing was rated as improved with MSCs following video review of second-look arthroscopy; blinding of this measure is unclear. There were limitations in study design (small sample size, short duration of follow-up). Also, significant improvements were found only on some outcomes, all significant differences in outcomes were modest in magnitude and, as a result, there is uncertainty about the clinical significance of the findings.

More recently, Zaffagnini et al (2022) reported on results of an RCT that evaluated a single intra-articular injection of microfragmented adipose tissue or PRP in patients (N=118) with knee OA. The primary outcomes were the IKDC subjective score and the KOOS pain subscore at 6 months. Overall, both treatments provided significant improvements from baseline in clinical outcomes, with no significant differences found between treatment groups. The IKDC scores significantly improved from baseline to 6 months, from 41.1 ± 16.3 to 57.3 ± 18.8 with microfragmented adipose tissue, and from 44.8 ± 17.3 to 58.4 ± 18.1 with PRP. The improvement in the KOOS pain subscore from baseline to 6 months was 58.4 ± 15.9 to 75.8 ± 17.4 with microfragmented adipose tissue and 63.5 ± 17.8 to 75.5 ± 16.1 with PRP. As a secondary outcome, more patients in the microfragmented adipose tissue group with moderate/severe knee OA reached the minimal clinically important difference for the IKDC score at 6 months compared with the PRP group (75.0% vs 34.6%, respectively; p=.005).

Kim et al (2023) reported a double-blind phase 3 RCT comparing a single intra-articular injection of autologous adipose tissue-derived MSCs with placebo in patients with knee OA (N=261). Patients meeting American College of Rheumatology criteria for Kellgren-Lawrence grade 3 knee OA who had 100 mm VAS pain scores ≥50 and WOMAC functional impairment scores ≥40 despites >3 months of non-operative treatment were eligible for enrollment. All patients underwent abdominal subcutaneous lipoaspiration 3 weeks prior to assigned study injection (1:1 randomization to $1x10^8$ autologous adipose tissue-derived MSCs [n=131] or a mixture of saline with autologous serum [n=130]). The co-primary endpoints were change in 100 mm VAS pain score and WOMAC function score from baseline to 6 months. In the primary analysis, patients assigned to adipose tissue-derived MSCs experienced significantly greater improvements than those assigned to placebo in both VAS pain score (25.2 ±24.6 vs 15.5 ±23.7; p=.004) and WOMAC function score (21.7 ±18.6 vs 14.3 ±19.2; p=.002) from baseline to 6 months. Six-month changes in patient-reported outcomes (KOOS, 36-Item Short Form Health Survey Score, and International Knee Documentation Committee subjective knee score) also reflected significant improvements in patients who received adipose tissue-derived MSCs compared with those who received placebo. Study limitations include that while patients were required to have received prior non-operative therapy for at least 3 months, specific prior treatments were not reported; it is unclear whether the use of a placebo comparator was more appropriate than an active comparator in this setting.

Mesenchymal Stem Cells from Peripheral Blood

A 2013 report from Asia has described a small RCT assessing the use of autologous peripheral blood MSCs for focal articular cartilage lesions. Fifty patients with grade 3 or 4 lesions of the knee joint underwent arthroscopic subchondral drilling followed by 5 weekly injections of HA. Half the patients were randomized to injections of peripheral blood stem cells or no further treatment. The peripheral blood stem cells were harvested after stimulation with recombinant human granulocyte colony- stimulating factor, divided in vials, and cryopreserved. At 6 months after surgery, HA and MSCs were re-administered over 3 weekly injections. At 18 months post-surgery, second-look arthroscopy on 16 patients in each group showed significantly higher histologic scores (»10%) for the MSC group (1066 vs. 957 by independent observers) while blinded evaluation of MRI scans showed a higher morphologic score (9.9 vs. 8.5). There was no difference in IKDC scores between the 2 groups at 24 months after surgery.

Mesenchymal Stem Cells from Umbilical Cord Blood

Lim et al (2021) reported on a RCT of 114 patients with large, full-thickness cartilage defects (International Cartilage Repair Society grade 4) treated with either a composite of umbilical cord-derived MSCs plus 4% hyaluronate (MSC-HA) or microfracture. The study consisted of a 48-week phase 3 clinical trial and a 5-year follow-up study. Of 114 patients randomized, 89 completed the phase 3 trial (78.1%), and 73 were enrolled in the follow-up study (64.0%). The primary outcome, proportion of participants with cartilage restoration equivalent to at least 1 grade improvement on the ICRS Macroscopic Cartilage Repair Assessment at 48-week arthroscopic evaluation, was 97.7% (42/43) in the MSC-HA group and 71.7% (33/46) in the microfracture group (odds ratio, 16.55; 95% CI, 2.06 to 133.03; p=.001). Both groups had significantly improved patient-reported pain scores (VAS pain, WOMAC, and IKDC scores) at 48 weeks versus baseline, but there was no significant difference between the 2 groups at this timepoint. From 36 to 60 months after intervention, the significant improvements from baseline were maintained in the MSC-HA group, whereas the improvements in VAS pain and WOMAC deteriorated in the microfracture group. This study had several limitations. There was no intervention group that received MSC alone, the comparator (microfracture) is not considered the standard of care for large, full-thickness cartilage defects, surgeons and participants were not blinded to treatment outcome, and there was high loss to follow-up. These limitations, along with a lack of improvement in patient-reported outcomes in the intervention group at 48 weeks, preclude drawing conclusions about the effectiveness of umbilical cord blood-derived MSCs in this population; higher quality evidence from RCTs is needed.

Xiao et al (2024) conducted a systematic review and meta-analysis on the effects of umbilical cord MSCs for the treatment of knee OA. The review included 3 RCTs (N=101), with study sample sizes ranging from 17 to 48. Results demonstrated significant reductions in WOMAC scores (mean difference, −25.85; 95% CI, −41.50 to −10.20; p=.001) and improvements in Knee Lysholm Scores (mean difference, 18.33; 95% CI, 12.89 to 23.77; p<.00001) in the MSC group compared to controls. Adverse events, including transient pain and joint effusion, were minimal. Limitations consisted of small sample sizes and study heterogeneity.

Mautner et al (2023) compared allogeneic umbilical cord blood-derived MSCs with corticosteroid injection in patients with OA in a single-blind RCT. The study is fully described above and in Tables 3 through 6.

Section Summary: Cartilage Defects

The evidence on MSCs for cartilage repair is increasing, although nearly all studies to date have been performed outside of the United States with a variety of methods of MSC preparation. Overall, the quality of evidence is low and there is a possibility of publication bias. The strongest evidence base is on MSCs

expanded from bone marrow, which includes several phase 1/2 RCTs and 1 phase 3 RCT. The phase 3 RCT of autologous bone marrow-derived MSCs also evaluated 2 other autologous and allogeneic cell therapies; the cell therapy modalities were not found to produce significant differences in pain or function after 12 months compared with intra-articular corticosteroid injection. An additional phase 3 trial evaluated autologous adipose tissue-derived MSCs; this trial enrolled patients with severe baseline symptoms and indicated significant improvements in pain, function, and other patient-reported outcomes at 6 months with intra-articular injection of adipose-derived MSCs relative to matching placebo. FDA approval for these methods has not been obtained.

Meniscal Defects

Clinical Context and Therapy Purpose

The purpose of stem cell therapy is to provide a treatment option that is an alternative to or an improvement on existing therapies in individuals with meniscal defects.

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is individuals with meniscal defects.

Interventions

The therapy being considered is stem cell therapy.

Comparators

Comparators of interest include conservative management.

Outcomes

The general outcomes of interest are symptoms, morbid events, functional outcomes, QOL, and TRM.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Review of Evidence

Damage to the meniscal cartilage in the knee is a very common orthopedic injury and predisposes to the development of OA. The tissue is relatively avascular and does not spontaneously heal well.

Whitehouse et al (2017) published a report on techniques of in vitro expansion of autologous-derived MSCs and a case series of the first-in-human implantation to treat meniscal defects in 5 patients.[21,] The regulatory framework in the United Kingdom allows cell manipulation and requires immunohistochemical documentation of the presence and volume of mesenchymal cells. Over the first 12 months post procedure, 3 of the 5 patients were reported to have clinical symptom relief, which persisted through 24 months. MRI scans showing lack of meniscal displacement were the only other postoperative assessment. The 2 patients who failed to obtain symptom relief at 6 and 12 months had to repeat arthroscopic procedures with meniscectomy.

Vangsness et al (2014) reported on an industry-sponsored phase 1/2 randomized, double-blind, multicenter Study of Chondrogen - Adult Universal Cell Delivered by Intra-Articular Injection Following Meniscectomy in Patients 18-60 Years (NCT00225095, NCT00702741) of cultured allogeneic MSCs (Chondrogen; Osiris Therapeutics) injected into the knee after partial meniscectomy.[22,] The 55 patients in this United States study were randomized to intra-articular injection of either $50´10^6$ allogeneic MSCs, $150´10^6$ allogeneic MSCs in HA, or an HA vehicle control at 7 to 10 days after meniscectomy. The cultured MSCs were derived from BMAC of unrelated donors. At 2-year follow-up, 3 patients in the low-dose MSC group had significantly increased meniscal volume measured by MRI (with an a priori determined threshold of at least 15%) compared with none in the control group or the high-dose MSC group. There was no significant difference between the groups in LKS scores. On subgroup analysis, patients with OA who received MSCs had a significantly greater reduction in pain at 2 years than patients who received HA alone. This trial appears to have been a post hoc analysis and, hence, should be considered preliminary. No serious adverse events were reported as related to the investigational treatment.

Section Summary: Meniscal Defect

The evidence on the use of MSCs to repair or regenerate damaged meniscal tissue consists of preclinical animal studies, first-in-human uncontrolled implantation of expanded autologous MSCs into meniscal tears, and an early-phase randomized trial of cultured allogeneic MSCs injected into the site of partial meniscectomy. Results are preliminary.

Joint Fusion Procedures

Clinical Context and Therapy Purpose

The purpose of stem cell therapy is to provide a treatment option that is an alternative to or an improvement on existing therapies in individuals with joint fusion procedures.

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is individuals with joint fusion procedures.

Interventions

The therapy being considered is stem cell therapy.

Comparators

Comparators of interest include iliac crest bone graft.

Outcomes

The general outcomes of interest are symptoms, morbid events, functional outcomes, QOL, and TRM.

Follow-up over months to years is of interest for relevant outcomes.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Review of Evidence

There is limited evidence on the use of allografts with stem cells for bone fusion of the extremities or spine or the treatment of nonunion. The results of several industry-sponsored, early-phase trials are available.

A prospective, clinical, and radiographic 12-month outcomes study (2016) of patients undergoing single-level anterior cervical discectomy and fusion (ACDF) for symptomatic cervical degenerative disc disease using a novel viable allogeneic stem cell and cancellous bone matrix (Trinity Evolution) was reported using historical controls as the comparator. The ACDF procedure was performed using the polyetheretherketone interbody spacer and bone graft substitute (Trinity Evolution) in 31 patients at multiple clinical sites. At 6 and 12 months, the primary endpoint of radiographic fusion was evaluated as determined by an independent radiographic review and the fusion rate was 78.6% at 6 months and 93.5% at 12 months. Secondary endpoints included a function as assessed by Neck Disability Index scores, and neck and arm pain as assessed by individual VAS scores. Neck function and neck and arm pain were reported as significantly improved at both 6- and 12-months post-procedure. Reported adverse events included carpal tunnel syndrome, minor pain, numbness, permanent and/or unresolved pain, and swelling. Independent medical adjudication of the 26 adverse events occurring in 31 patients found that no adverse events were definitely or probably related to Trinity Evolution. However, 5 adverse events were found to be possibly related to Trinity Evolution with 3 events of mild severity and 2 of moderate severity.

A similar study (2017) involving several of the same investigators and clinical sites reported on the clinical and radiographic evaluation of an allogeneic bone matrix containing stem cells (Trinity Evolution Viable Cellular Bone Matrix) in patients undergoing 2-level ACDF. This study involved 40 patients exposed to the ACDF and bone graft substitute procedure at 2 adjacent disc levels. A panel blinded to clinical outcomes

reviewed 12-month dynamic motion plain radiographs and thin-cut computed tomography with multiplanar reconstruction. At 12 months, the per-subject and per-level fusion rates were 89.4% and 93.4%, respectively. The clinical function assessments using the Neck Disability Index and VAS scores were reported to have improved from baseline.

A 2015 prospective, multicenter, open-label clinical trial using a cryopreserved, donor mesenchymal cell scaffold (Trinity Evolution) was performed in subjects undergoing foot and/or ankle arthrodesis with surgeons' preferred technique. A total of 103 subjects were prospectively enrolled at 10 participating sites. No restrictions were placed on the diagnosis, which included arthritis (primary OAs, posttraumatic OA, and rheumatoid), deformity, neuropathy (Charcot and diabetic), revision surgery, and degenerative joint disease, and arthrodesis was performed in 171 joints. The per-protocol population consisted of 92 patients at 6 months and 76 patients at 12 months, with 153 and 129 total arthrodesis, respectively. The primary endpoint was fusion at 6 months, as assessed from computed tomography scans and standard radiographs by an independent radiology consultant. At 6 months, the fusion rate for all patients was 68.5% and 81.1% for all joints. American Orthopaedic Foot and Ankle Society Hindfoot Scale scores for disability improved over time.

Eastlack et al (2014) reported on outcomes from a series of 182 patients treated with ACDF using Osteocel Plus in a polyetheretherketone cage and anterior plating. At 24 months, 74% of patients (180/249 levels treated) were available for follow-up. These patients had significant improvements in clinical outcomes, with 87% of levels achieved solid bridging, and 92% of levels had a range of motion less than 3°. With 26% loss to follow-up at 24 months and lack of a standard of care control group, interpretation of these results is limited.

Section Summary: Joint Fusion Procedures

The evidence on the use of MSCs as a component of joint fusion procedures primarily comes from industry-sponsored, prospective, open-label procedures. Outcomes included radiologic assessments of fusion, sometimes made independently, and patient-reported measures (e.g., VAS scores). The MSCs used were cryopreserved allogeneic in origin. Presumptive benefits of allogeneic MSCs are that patients undergoing an orthopedic intervention procedure do not need another graft harvesting procedure and that dose of stem cells can be managed.

Osteonecrosis

Clinical Context and Test Purpose

The purpose of stem cell therapy is to provide a treatment option that is an alternative to or an improvement on existing therapies in individuals with osteonecrosis.

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is individuals with osteonecrosis.

Interventions

The therapy being considered is therapy with MSCs.

Comparators

Comparators of interest include core decompression.

Outcomes

The general outcomes of interest are symptoms, morbid events, functional outcomes, QOL, and TRM.

Follow-up over months to years is of interest for relevant outcomes.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Review of Evidence

At least 2 RCTs from Asia have evaluated the use of MSCs for osteonecrosis of the femoral head.

Mesenchymal Stem Cells Concentrated from Bone Marrow Aspirate Concentrate

Sen et al (2012) randomized 40 patients (51 hips) with early-stage femoral head osteonecrosis to core decompression plus concentrated bone marrow MSCs or core decompression alone. Blinding of assessments in this small trial was not described. Harris Hip Score was significantly improved in the core decompression plus MSC group compared with the core decompression alone group at 12 months (scores, 83.65 vs. 76.68, p<.016) but not at 24 months (scores, 82.42 vs. 77.39; p=.09), all respectively. Kaplan-Meier analysis showed improved hip survival in the MSC group (mean, 51.9 weeks) compared with the core decompression group (mean, 46.7 weeks). There were no significant differences between groups in radiographic assessment or MRI results.

Mesenchymal Stem Cells Expanded from Bone Marrow

Zhao et al (2012) reported on a randomized trial that included 100 patients (104 hips) with early-stage femoral head osteonecrosis treated with core decompression and expanded bone marrow MSCs or with core decompression alone. At 60 months post-surgery, 2 (3.7%) of the 53 hips treated with MSCs progressed and underwent vascularized bone grafting compared with 10 (23%) of 44 hips in the decompression group who progressed and underwent either vascularized bone grafting (n=5) or total hip replacement (n=5). The MSC group also had improved Harris Hip Scores compared with the control group on independent evaluation (data presented graphically). Lesion volume was also reduced by treatment with MSCs.

Section Summary: Osteonecrosis

Two small RCTs have compared core decompression alone with core decompression plus MSCs in patients with osteonecrosis of the femoral head. Both reported improvement in the Harris Hip Score in patients treated with MSCs, although it was not reported whether the patients or investigators were blinded to the treatment group. Hip survival was significantly improved following treatment with either expanded or concentrated MSCs. The effect appears to be larger with expanded MSCs than with concentrated MSCs. Additional, well-designed RCTs with a large number of patients are needed to permit greater certainty on the efficacy of this treatment for osteonecrosis.

SUPPLEMENTAL INFORMATION

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in ‘Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Academy of Orthopaedic Surgeons (AAOS)

In 2020, from American Academy of Orthopaedic Surgeons (AAOS) on the management of glenohumeral joint osteoarthritis (OA), endorsed by several other societies, states that injectable Biologics such as stem cells cannot be recommended in the treatment of glenohumeral osteoarthritis (OA). There was consensus from the panel that better standardization and high-quality evidence from clinical trials is needed to provide definitive evidence on the efficacy of biologics in glenohumeral OA. The strength of evidence was rated as no reliable scientific evidence to determine benefits and harms.

The 2021 guideline on treatment of osteoarthritis of the knee does not address stem cell injections.

The 2023 guidelines on treatment of osteoarthritis of the hip do not address stem cell injections.

American Association of Neurological Surgeons

In 2014, the American Association of Neurological Surgeons (AANS) guideline on fusion procedures for degenerative disease of the lumbar spine relevant to this evidence review have indicated that “The use of demineralized bone matrix (DBM) as a bone graft extender is an option for 1 and 2 level instrumented posterolateral fusions. Demineralized Bone Matrix: Grade C (poor level of evidence).”

American College of Rheumatology and Arthritis Foundation

In 2019, guidelines from the American College of Rheumatology and Arthritis Foundation on osteoarthritis on the hand, hip and knee which included the following recommendation:

- Stem cell injections are strongly recommended *against* in patients with knee and/or hip OA.

- There is concern regarding the heterogeneity and lack of standardization in available preparations of stem cell injections, as well as techniques used. This treatment has not been evaluated in hand OA and, therefore, no recommendation is made with regard to OA of the hand.

Ongoing and Unpublished Clinical Trials

Some currently ongoing and unpublished trials that might influence this review can be located at clinicaltrials.gov.

REFERENCES

1. U.S. Food and Drug Administration. Ensuring Safety and Efficacy of Stem Cell Based Products. Accessed May 14, 2014
2. U.S. Food and Drug Administration. Untitled Letters (Biologics), Regenerative Sciences, Inc. Guidance, Compliance and Regulatory Information (Biologics) 2008. Accessed May 14, 2014
3. American Academy of Orthopaedic Surgeons (AAOS), OrthoInfo, Your connection to expert orthopaedic information, Stem Cells and Orthopaedics. Accessed May 2, 2014
4. American Academy of Orthopaedic Surgeons (AAOS), OrthoInfo, Your connection to expert orthopaedic information, Frequently Asked Questions about Stem Cells. Accessed May 2, 2014
5. International Congress for Joint Reconstruction (ICJR). Reports, Looking Toward the Future of Stem Cells in Orthopaedics. Accessed May 15, 2014
6. International Society for Cellular Therapy (ISCT), Position Paper, Minimal Criteria for Defining Multipotent Mesenchymal Stromal Cells. The International Society for Cellular Therapy Position Statement. Cryotherapy (2006) Vol. 8, No.4, 315-317.
7. Sally Roberts, et al. Prospects of Stem Cell Therapy in Osteoarthritis. Regen.Med (2011) 6(3), 351-366.
8. Shaul Beyth, Josh Schroeder and Meir Liebergall, Stem Cells in Bone Diseases: Current Clinical Practice. British Medical Bulletin 2011; 99:199-210
9. Christopher J. Centeno and Stephen J. Faulkner, Chapter 21, The Use of Mesenchymal Stem Cells in Orthopedics. M.A. Hayat (ed), Stem Cells and Cancer Stem Cells, Volume 1, DOI 10.1007/978-94-007-1709-1-21.
10. Medscape. Technology Insight: Adult Mesenchymal Stem Cells for Osteoarthritis Therapy.
11. Dominici M, Le Blanc K, Mueller I, et. al. Minimal Criteria for Defining Multipotent Mesenchymal Stromal Cells. The International Society for Cellular Therapy Position Statement. Cytotherapy 2006;8(4):315-7
12. Rush SM, Hamilton GA, Ackerson LM, Mesenchymal Stem Cell Allograft in Revision Foot and Ankle Surgery: A clinical and Radiographic Analysis. J Foot Ankle Surg 2009; 48(2):163-9
13. Centeno CJ, Schultz JR, Cheever M, et. al. Safety and Compliations Reporting on Re-Implantation of Culture Expanded Mesenchymal Stem Cells Using Autologous Platelet Lysate Technique, Curr Stem Cell Rews Ther, 2011, 6, 368-378
14. Andre F. Steinert, Lars Rackwitz, et. al. Concise Review: The Clinical Application of Mesenchymal Stem Cells for Musculoskeletal Regeneration: Current States and Perspectives, Stem Cells Translational Medicine 2012;1:237-247.
15. Rick L Lau, Anthony V. Perruccio, et. al. Stem Cell Therapy for the Treatment of Early Stage Avascular Necrosis of the Femoral Head: A Systematic Review, BMC Musculoskeletal Disorders 2014, 15:156.
16. Jonathan I. Dawson, Janos Kanczler, et. al. Concise Review: Bridging the Gap: Bone Regeneration Using Skeletal Stem Cell-Based Strategies-Where Are We Now?, Stem Cells Volume 32, Issue 1 January 2014

17. Filardo G, Madry H, et. al.Mesenchymal Stem Cells for the Treatment of Cartilage Lesions: From Preclinical Findings to Clinical Application in Orthopaedics. Knee Surg Sports Traumatol Arthrosc 2013 aug;21(8):1717-29
18. Wong KL, Lee KB, Tai BC et. al. Injectable Cultured Bone Marrow-Derived Mesenchymal Stem Cells in Varus Knees with Cartilage Defects Undergoing High Tibial Osteotomy: A Prospective, Randomized Controlled Clinical Trial with 2 Years Follow Up. Arthroscopy 2013; 29(12):2020-8
19. Hana Yu, Adetola B Adesida and Nadr M Jomha, Meniscus Repair Using Mesenchymal Stem Cells – A Comprehensive Review. Stem Cell Research & Therapy 2015 6:86
20. Orthofix Trinity Evolution Matrix Allograft with Viable Cells.
21. Allosource Allostem Cellular Bone Allograft.
22. RTIX Map3 Cellular Allogeneic Bone Graft.
23. Nuvasive Osteocel Plus Bone Grafting.
24. Centeno Christopher, Pitts John, et. al. Efficacy and Safety of Bone Marrow Concentrate for Osteoarthritis of the Hip: Treatment Registry Results of 196 Patients, Journal Stem Cell Research and Therapy 2014, Volume 4 Issue 10
25. Centeno Christopher, Pitts John, et. al. Efficacy of Autologous Bone Marrow Concentrate for Knee Osteoarthritis with and without Adipose Graft, BioMed Research International, September 2014,
26. Veronesi F, Giavaresi G, et. al. Clinical Use of Bone Marrow, Bone Marrow Concentrate, and Expanded Bone Marrow Mesenchymal Stem Cells in Cartilage Disease, Stem Cells Dev. 2013 Jan 15;22(2):181-92
27. Hernigou P, Flouzat Lachaniette CH, et. al. Biologic Augmentation of Rotator Cuff Repair with Mesenchymal Stem Cells During Arthroscopy Improves Healing and Prevents Further Tears: A Case-Controlled Study, Int Orthop 2014 Sep;38(9):1811-8
28. Centeno CJ, Busse D, et. al. Regeneration of Meniscus Cartilage in a Knee Treated with Percutaneously Implanted Autologous Mesenchymal Stem Cells, Med Hyptheses 2008 Dec; 71(6):900-8
29. Bashir J, Sherman A., et. al. Mesenchymal Stem Cell Therapies in the Treatment of Musculoskeletal Diseases, Physical Medicine and Rehabilitation 2014 Jan;6(1):61-9
30. Houdek Matthew, Wyle Cody, et. al. Stem Cell Treatment for Avascular Necrosis of the Femoral Head: Current Perspectives, Stem Cells and Cloning: Advances and Applications 2014:7 65-70
31. Carpenter RS, Goodrich LR, Frisbie DD, Kisiday JD, Carbone B, Mcllwraith, CJ Centeno, and C Hidaka, Osteoblastic Differentiation of Human and Equine Adult Bone Marrow-Derived Mesenchymal Stem Cells when BMP-2 or BMP-7 Homodimer Genetic Modification is Compared to BMP-2/7 Heterodimer Genetic Modification in the Presence and Absence of Dexamethasone, J Orthop Res. 2010 October; 28(10): 1130-1337
32. Peters C.M.M., Leijs M.J.C., et. al. Safety of Intra-Articular Cell-Therapy with Culture Expanded Stem Cells in Humans: A Systemic Literature Review, Osteoarthritis Research Society International June 2013,
33. Centeno CJ, Freeman MD, Percutaneous Injection of Autologous, Culture Expanded Mesenchymal Stem Cells into Carpometacarpal Hand Joints: A Case Series with an Untreated Comparison Group, Wien Med Wochenschr 2014 Mar;164(5-6):83-7
34. Centeno Christopher, Schultz John, et. al. A Case Series of Percutaneous Treatment of Non-Union Fractures with Autologous, Culture Expanded, Bone Marrow Derived, Mesenchymal Stem Cells and Platelet Lysate, Bioengineering and Biomedical Science,
35. Chirba MA, Sweetapple B, Hannon CP, et al. FDA regulation of adult stem cell therapies as used in sports medicine. J Knee Surg. Feb 2015;28(1):55-62. PMID 25603042
36. Filardo G, Madry H, Jelic M, et al. Mesenchymal stem cells for the treatment of cartilage lesions: from preclinical findings to clinical application in orthopaedics. Knee Surg Sports Traumatol Arthrosc. Aug 2013;21(8):1717-1729. PMID 23306713
37. Wong KL, Lee KB, Tai BC, et al. Injectable cultured bone marrow-derived mesenchymal stem cells in varus knees with cartilage defects undergoing high tibial osteotomy: a prospective, randomized

controlled clinical trial with 2 years' follow-up. Arthroscopy. Dec 2013;29(12):2020-2028. PMID 24286801
38. Wakitani S, Imoto K, Yamamoto T, et al. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. Osteoarthritis Cartilage. Mar 2002;10(3):199-206. PMID 11869080
39. Wakitani S, Nawata M, Tensho K, et al. Repair of articular cartilage defects in the patello-femoral joint with autologous bone marrow mesenchymal cell transplantation: three case reports involving nine defects in five knees. J Tissue Eng Regen Med. Jan-Feb 2007;1(1):74-79. PMID 18038395
40. Wakitani S, Okabe T, Horibe S, et al. Safety of autologous bone marrow-derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed for up to 11 years and 5 months. J Tissue Eng Regen Med. Feb 2011;5(2):146-150. PMID 20603892
41. Nejadnik H, Hui JH, Feng Choong EP, et al. Autologous bone marrow-derived mesenchymal stem cells versus autologous chondrocyte implantation: an observational cohort study. Am J Sports Med. Jun 2010;38(6):1110-1116. PMID 20392971
42. Vega A, Martin-Ferrero MA, Del Canto F, et al. Treatment of knee osteoarthritis with allogeneic bone marrow mesenchymal stem cells: a randomized controlled trial. Transplantation. Aug 2015;99(8):1681-1690. PMID 25822648
43. Giannini S, Buda R, Vannini F, et al. One-step bone marrow-derived cell transplantation in talar osteochondral lesions. Clin Orthop Relat Res. Dec 2009;467(12):3307-3320. PMID 19449082
44. Giannini S, Buda R, Cavallo M, et al. Cartilage repair evolution in post-traumatic osteochondral lesions of the talus: from open field autologous chondrocyte to bone-marrow-derived cells transplantation. Injury. Nov 2010;41(11):1196-1203. PMID 20934692
45. Centeno CJ, Al-Sayegh H, Bashir J, et al. A prospective multi-site registry study of a specific protocol of autologous bone marrow concentrate for the treatment of shoulder rotator cuff tears and osteoarthritis. J Pain Res. 2015;8:269-276. PMID 26089699
46. Koh YG, Kwon OR, Kim YS, et al. Comparative outcomes of open-wedge high tibial osteotomy with platelet-rich plasma alone or in combination with mesenchymal stem cell treatment: a prospective study. Arthroscopy. Nov 2014;30(11):1453-1460. PMID 25108907
47. Kim YS, Park EH, Kim YC, et al. Clinical outcomes of mesenchymal stem cell injection with arthroscopic treatment in older patients with osteochondral lesions of the talus. Am J Sports Med. May 2013;41(5):1090-1099. PMID 23460335
48. Kim YS, Lee HJ, Choi YJ, et al. Does an injection of a stromal vascular fraction containing adipose-derived mesenchymal stem cells influence the outcomes of marrow stimulation in osteochondral lesions of the talus? A clinical and magnetic resonance imaging study. Am J Sports Med. Oct 2014;42(10):2424-2434. PMID 25106781
49. Koh YG, Choi YJ. Infrapatellar fat pad-derived mesenchymal stem cell therapy for knee osteoarthritis. Knee. Dec 2012;19(6):902-907. PMID 22583627
50. Jo CH, Lee YG, Shin WH, et al. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. Stem Cells. May 2014;32(5):1254-1266. PMID 24449146
51. Saw KY, Anz A, Siew-Yoke Jee C, et al. Articular cartilage regeneration with autologous peripheral blood stem cells versus hyaluronic acid: a randomized controlled trial. Arthroscopy. Apr 2013;29(4):684-694. PMID 23380230
52. Akgun I, Unlu MC, Erdal OA, et al. Matrix-induced autologous mesenchymal stem cell implantation versus matrix-induced autologous chondrocyte implantation in the treatment of chondral defects of the knee: a 2-year randomized study. Arch Orthop Trauma Surg. Feb 2015;135(2):251-263. PMID 25548122
53. Vangsness CT, Jr., Farr J, 2nd, Boyd J, et al. Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy: a randomized, double-blind, controlled study. J Bone Joint Surg Am. Jan 15 2014;96(2):90-98. PMID 24430407

54. Eastlack RK, Garfin SR, Brown CR, et al. Osteocel plus cellular allograft in anterior cervical discectomy and fusion: evaluation of clinical and radiographic outcomes from a prospective multicenter study. Spine (Phila Pa 1976). Oct 15 2014;39(22):E1331-1337. PMID 25188591
55. Zhao D, Cui D, Wang B, et al. Treatment of early stage osteonecrosis of the femoral head with autologous implantation of bone marrow-derived and cultured mesenchymal stem cells. Bone. Jan 2012;50(1):325-330. PMID 22094904
56. Sen RK, Tripathy SK, Aggarwal S, et al. Early results of core decompression and autologous bone marrow mononuclear cells instillation in femoral head osteonecrosis: a randomized control study. J Arthroplasty. May 2012;27(5):679-686. PMID 22000577
57. Centeno C, Al-Sayegh H, Freeman M, et. al. A multi-center analysis of adverse events among two thousand, three hundred and seventy two adult patients undergoing adult autologous stem cell therapy for orthopaedic conditions. International Orthopaedics (SICOT) 2016 40:1755-1765
58. Centeno CJ, Schultz JR, Cheever M, et. al. Safety and complications reporting on the reimplantation of culture expanded mesenchymal stem cells using autologous platelet lysate technique. Curr Stem Cell Res Ther Dec 2, 2010;5(1):81-93. PMID 19951252
59. Goldberg A, Mitchell K, Soans J, et al. The use of mesenchymal stem cells for cartilage repair and regeneration: a systematic review. Mar 09 2017;12(1):39. PMID 28279182
60. Shapiro SA, Kazmerchak SE, Heckman MG, et al. A prospective, single-blind, placebo-controlled trial of bone marrow aspirate concentrate for knee osteoarthritis. Am J Sports Med. Jan 2017;45(1):82-90. PMID 27566242
61. Borakati A, Mafi R, Mafi P, et al. A systematic review and meta-analysis of clinical trials of mesenchymal stem cell therapy for cartilage repair. Curr Stem Cell Res Ther. Sep 15 2017. PMID 28914207
62. Jo CH, Chai JW, Jeong EC, et al. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a 2-year follow-up study. Am J Sports Med. Oct 2017;45(12):2774-2783. PMID 28746812
63. Whitehouse MR, Howells NR, Parry MC, et al. Repair of torn avascular meniscal cartilage using undifferentiated autologous mesenchymal stem cells: from in vitro optimization to a first-in-human study. Stem Cells Transl Med. Apr 2017;6(4):1237-1248. PMID 28186682
64. Vanichkachorn J, Peppers T, Bullard D, et al. A prospective clinical and radiographic 12-month outcome study of patients undergoing single-level anterior cervical discectomy and fusion for symptomatic cervical degenerative disc disease utilizing a novel viable allogeneic, cancellous, bone matrix (trinity evolution) with a comparison to historical controls. *Eur Spine J.* Jul 2016;25(7):2233-2238. PMID 26849141
65. Peppers TA, Bullard DE, Vanichkachorn JS, et al. Prospective clinical and radiographic evaluation of an allogeneic bone matrix containing stem cells (Trinity Evolution(R) Viable Cellular Bone Matrix) in patients undergoing two-level anterior cervical discectomy and fusion. J Orthop Surg Res. Apr 26 2017;12(1):67. PMID 28446192
66. Jones CP, Loveland J, Atkinson BL, et al. Prospective, multicenter evaluation of allogeneic bone matrix containing viable osteogenic cells in foot and/or ankle arthrodesis. Foot Ankle Int. Oct 2015;36(10):1129-1137. PMID 25976919
67. Kaiser MG, Groff MW, Watters WC, et. al. Guideline update for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 16: bone graft extenders and substitutes as an adjunct for lumbar fusion. J Neurosurg Spine Jul 2014;2191):106-132. PMID 24980593
68. Lee KB, Wang VT, Chan YH, et. al. A novel, minimally-invasive technique of cartilage repair in the human knee using arthroscopic microfracture and injections of mesenchymal stem cells and hyaluronic acid-a prospective comparative study on safety and short-term efficacy. Ann Acad Med Singapore 2012 Nov:41(11):511-7. PMID 23235728
69. Liebergall M, Schroeder J, Mosheiff R, et. al. Stem call based therapy for prevention of delayed fracture union: a randomized and prospective preliminary study. Mol Ther 2013 Aug;21(8):1631-8.

70. Piccirilli M, Delfinis CP, Santoro A, et. al. Mesenchymal stem cells in lumbar spine surgery: a single institution experience about red bone marrow and fat tissue derived MSCs. J Neurosurg Sci 2017 Apr;61(2):124-133. PMID 26082381
71. Shao J, Zhang W, Yang T. Using mesenchymal stem cells as therapy for bone regeneration and repairing. Biol Res 2015;48:62. PMID 26530042
72. Vigano M, Sansone V, et. al. Mesenchymal stem cells as therapeutic target of biophysical stimulation for the treatment of musculoskeletal disorders. Journal of Orthopaedic Surgery and Research 2016 11:163
73. American Academy of Orthopaedic Surgeons (AAOS) Position statement on the use of emerging biologic therapies. 2017. Also available at https://www.asso.org
74. American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines: Anterior Cruciate Ligament Injuries.
75. American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines: Glenohumeral Joint Arthritis.
76. American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines: Osteoarthritis of the Hip.
77. American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines: Osteoarthritis of the knee (Non-Arthroplasty).
78. American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines Rotator Cuff Problems. Also available at https://www.aaos.org
79. Akpancar S, Tatar O, Turgut H, et. al. The current perspectives of stem cell therapy in orthopedic surgery. Arch Trauma Res 2016 December 5(4):E37976
80. Giuseppe Usuelli F, D'Ambrosi R, Maccario C, et. al. Adipose-derived stem cells in orthopaedic pathologies. British Medical Bulletin 2017 124:31-54
81. UpToDate. Management of Rotator Cuff Tears. Topic last updated November 2024. Also available at https//www.uptodate.com
82. Burke J, Hunter M, Kolhe R, Isales C, Hamrick M, Fulzele S. Therapeutic potential of mesenchymal stem cell based therapy for osteoarthritis. Clin Transl Med. 2016 Dec;5(1):27
83. Centeno CJ, Al-Sayegh H, Freeman MD ,et al. A multi-center analysis of adverse events among two thousand, three hundred and seventy two adult patients undergoing adult autologous stem cell therapy for orthopaedic conditions. Int Orthop. 2016 Aug;40(8):1755-1765
84. Centeno C, Sheinkop M, Dodson D, et al. A specific protocol of autologous bone marrow concentrate and platelet products versus exercise therapy for symptomatic knee osteoarthritis: a randomized controlled trial with 2 year follow-up. J Trans Med. 2018b; 16:355
85. Chew E, Prakash R, Khan W. Mesenchymal stem cells in human meniscal regeneration: A systematic review. Ann Med Surg (Lond). 2017 Oct 5;24:3-7
86. Delanois RE, Etcheson JI, Sodhi N, Henn RF 3rd, Gwam CU, George NE, Mont MA. Biologic Therapies for the Treatment of Knee Osteoarthritis. J Arthroplasty. 2019 Apr;34(4):801-813
87. Di Matteo B, El Araby MM, D'Angelo A, et al. Adipose-Derived Stem Cell Treatments and Formulations. Clin Sports Med. 2019 Jan;38(1):61-78
88. Di Matteo B, Vandenbulcke F Vitale ND, et al. Minimally Manipulated Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis: A Systematic Review of Clinical Evidence. Stem Cells Int. 2019 Aug 14;2019:1735242
89. Emadedin M, Labibzadeh N, Liastani MG, et al. Intra-articular implantation of autologous bone marrow-derived mesenchymal stromal cells to treat knee osteoarthritis: a randomized, triple-blind, placebo-controlled phase 1/2 clinical trial. Cytotherapy. 2018 Oct;20(10):1238-1246
90. Ha CW, Park YB, Kim SH, Lee HJ. Intra-articular Mesenchymal Stem Cells in Osteoarthritis of the Knee: A Systematic Review of Clinical Outcomes and Evidence of Cartilage Repair. Arthroscopy. 2019 Jan;35(1):277-288.e2
91. Hurley ET, Yasui Y, Gianakos AL, et al. Limited evidence for adipose-derived stem cell therapy on the treatment of osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2018 Nov;26(11):3499-3507

92. International Society for Stem Cell Research. Types of stem cells. © 2019 International Society of Stem Cell Research. Accessed October 25, 2019. Available at address: https://www.closerlookatstemcells.org/learn-about-stem-cells/types-of-stem-cells
93. Kehoe O, Cartwright A, Askari A, El Haj AJ, Middleton J. Intra-articular injection of mesenchymal stem cells leads to reduced inflammation and cartilage damage in murine antigen-induced arthritis. J Transl Med. 2014 Jun 3;12:157
94. Khan S, Mafi P, Mafi R, Khan W. A Systematic Review of Mesenchymal Stem Cells in Spinal Cord Injury, Intervertebral Disc Repair and Spinal Fusion. Curr Stem Cell Res Ther. 2018;13(4):316-323
95. Lee WY, Wang B. Cartilage repair by mesenchymal stem cells: Clinical trial update and perspectives. J Orthop Translat. 2017 Apr 9;9:76-88
96. Lin KM, Wang D, Dines JS. Injection therapies for rotator cuff disease. Orthop Clin N Am 49 (2018) 231–239
97. Marks PW, Witten CM, Califf RM. Clarifying Stem-Cell Therapy's Benefits and Risks. N Engl J Med. 2017 Mar 16;376(11):1007-1009
98. Migliorini F, Rath B, Colarossi G, et al. Improved outcomes after mesenchymal stem cells injections for knee osteoarthritis: results at 12-months follow-up: a systematic review of the literature. Arch Orthop Trauma Surg. 2019 Aug 27
99. Pak J. Regeneration of human bones in hip osteonecrosis and human cartilage in knee osteoarthritis with autologous adipose-tissue-derived stem cells: a case series. J Med Case Rep. 2011 Jul 7;5:296
100. Pak J, Lee JH, Pak N, et al. Cartilage Regeneration in Humans with Adipose Tissue-Derived Stem Cells and Adipose Stromal Vascular Fraction Cells: Updated Status. Int J Mol Sci. 2018 Jul 23;19(7)
101. Panchal J, Malanga G, Sheinkop M. Safety and Efficacy of Percutaneous Injection of Lipogems Micro-Fractured Adipose Tissue for Osteoarthritic Knees. Am J Orthop (Belle Mead NJ). 2018 Nov;47(11)
102. Park YB, Ha CW, Rhim JH, Lee HJ. Stem Cell Therapy for Articular Cartilage Repair: Review of the Entity of Cell Populations Used and the Result of the Clinical Application of Each Entity. Am J Sports Med. 2018 Aug;46(10):2540-2552
103. Pas HI, Winters M, Haisma HJ, Koenis MJ, Tol JL, Moen MH. Stem cell injections in knee osteoarthritis: a systematic review of the literature. Br J Sports Med. 2017a Aug;51(15):1125-1133
104. Pas HIMFL, Moen MH, Haisma HJ, Winters M. No evidence for the use of stem cell therapy for tendon disorders: a systematic review. Br J Sports Med. 2017b Jul;51(13):996-1002
105. Roffi A, Nakamura N, Sanchez M, Cucchiarini M, Filardo G. Injectable Systems for Intra-Articular Delivery of Mesenchymal Stromal Cells for Cartilage Treatment: A Systematic Review of Preclinical and Clinical Evidence. Int J Mol Sci. 2018 Oct 25;19(11)
106. Tremolada C, Colombo V, Ventura C. Adipose Tissue and Mesenchymal Stem Cells: State of the Art and Lipogems® Technology Development. Curr Stem Cell Rep. 2016;2:304-312
107. United States Food and drug Administration. Lipogems system. 510(k) approval (K161636). September 2016. Accessed October 11, 2019. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf16/K161636.pdf
108. Uth K, Trifonov D. Stem cell application for osteoarthritis in the knee joint: A minireview. World J Stem Cells. 2014 Nov 26;6(5):629-36
109. Vadalà G, Russo F, Ambrosio L, Loppini M, Denaro V. Stem cells sources for intervertebral disc regeneration. World J Stem Cells. 2016 May 26;8(5):185-201
110. Vannabouathong C, Del Fabbro G, Sales B, Intra-articular Injections in the Treatment of Symptoms from Ankle Arthritis: A Systematic Review. Foot Ankle Int. 2018 Oct;39(10):1141-1150
111. Wang M, Yuan Q, Xie L. Mesenchymal Stem Cell-Based Immunomodulation: Properties and Clinical Application. Stem Cells Int. 2018 Jun 14;2018:3057624
112. Wang Y, Han ZB, Song YP, Han ZC. Safety of mesenchymal stem cells for clinical application. Stem Cells Int. 2012;2012:652034

113. Szabo L/Kaiser Health News Employers are Steering Workers Toward Controversial Stem Cell Therapies. Time Health June 19, 2019.
114. AAOS Releases Position Statement on the Use of Emerging Biologic Therapies. December 2020 Position Statement 1187
115. Kim GB and Shon OJ. Current perspectives in stem cell therapies for osteoarthritis of the knee. Yeungnam University Journal of Medicine 2020;37(3):149-158
116. Muthu, S, Mir, AA, Kumar, R, Yadav, V, Jeyaraman, M, and Khanna, M. What is the clinically significant ideal mesenchymal stromal cell count in the management of osteoarthritis of the knee? – Meta-analysis of randomized controlled trials. J Clin Orthop Trauma. 2022;25:101744.
117. Agarwal, N, Mak, C, Bojanic, C, To, K, and Khan, W. Meta-Analysis of Adipose Tissue Derived Cell-Based Therapy for the Treatment of Knee Osteoarthritis. Cells. 2021;10(6).
118. Dai, W, Leng, X, Wang, J, Shi, Z, Cheng, J, Hu, X, and Ao, Y. Intra-Articular Mesenchymal Stromal Cell Injections Are No Different From Placebo in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Arthroscopy. 2021;37(1):340-358.
119. Jeyaraman, M, Muthu, S, and Ganie, PA. Does the Source of Mesenchymal Stem Cell Have an Effect in the Management of Osteoarthritis of the Knee? Meta-Analysis of Randomized Controlled Trials. Cartilage. 2021;13(1_suppl):1532s-1547s..
120. Naja, M, Fernandez De Grado, G, Favreau, H, Scipioni, D, Benkirane-Jessel, N, Musset, AM, and Offner, D. Comparative effectiveness of nonsurgical interventions in the treatment of patients with knee osteoarthritis: A PRISMA-compliant systematic review and network meta-analysis. Medicine (Baltimore). 2021;100(49): e28067.
121. Qu, H, and Sun, S. Efficacy of mesenchymal stromal cells for the treatment of knee osteoarthritis: a meta-analysis of randomized controlled trials. J Orthop Surg Res. 2021;16(1):11.
122. Tan, SHS, Kwan, YT, Neo, WJ, Chong, JY, Kuek, TYJ, See, JZF, Wong, KL, Toh, WS, et al. Intra-articular Injections of Mesenchymal Stem Cells Without Adjuvant Therapies for Knee Osteoarthritis: A Systematic Review and Meta-analysis. Am J Sports Med. 2021;49(11):3113-3124.
123. Wiggers, TG, Winters, M, Van den Boom, NA, Haisma, HJ, and Moen, MH. Autologous stem cell therapy in knee osteoarthritis: a systematic review of Randomized controlled trials. Br J Sports Med. 2021;55(20):1161-1169.
124. Zhao, D, Pan, JK, Yang, WY, Han, YH, Zeng, LF, Liang, GH, and Liu, J. Intra-Articular Injections of Platelet-Rich Plasma, Adipose Mesenchymal Stem Cells, and Bone Marrow Mesenchymal Stem Cells Associated With Better Outcomes Than Hyaluronic Acid and Saline in Knee Osteoarthritis: A Systematic Review and Network Meta-analysis. Arthroscopy. 2021;37(7):2298-2314.e2210.
125. Boffa, A, Previtali, D, Di Laura Frattura, G, Vannini, F, Candrian, C, and Filardo, G. Evidence on ankle injections for osteochondral lesions and osteoarthritis: a systematic review and meta-analysis. Int Orthop. 2021;45(2):509-523.
126. Anil, U, Markus, DH, Hurley, ET, Manjunath, AK, Alaia, MJ, Campbell, KA, Jazrawi, LM, and Strauss, EJ. The efficacy of intra-articular injections in the treatment of knee osteoarthritis: A network meta-analysis of randomized controlled trials. Knee. 2021;32:173-182.
127. Bolia, IK, Bougioukli, S, Hill, WJ, Trasolini, NA, Petrigliano, FA, Lieberman, JR, and Weber, AE. Clinical Efficacy of Bone Marrow Aspirate Concentrate Versus Stromal Vascular Fraction Injection in Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis. Am J Sports Med. 2021:3635465211014500.
128. Cao, Z, Li, Y, Gao, F, Wu, R, Dou, P, Wang, W, and Li, Q. Mesenchymal Stem Cells: A New Choice for Nonsurgical Treatment of OA? Results from a Bayesian Network Meta-Analysis. Biomed Res Int. 2021;2021:6663003.
129. Han, SB, Seo, IW, and Shin, YS. Intra-Articular Injections of Hyaluronic Acid or Steroids Associated With Better Outcomes Than Platelet-Rich Plasma, Adipose Mesenchymal Stromal

Cells, or Placebo in Knee Osteoarthritis: A Network Meta-analysis. Arthroscopy. 2021;37(1):292-306.
130. Jiang, P, Mao, L, Qiao, L, Lei, X, Zheng, Q, and Li, D. Efficacy and safety of mesenchymal stem cell injections for patients with osteoarthritis: a meta-analysis and review of RCTs. Arch Orthop Trauma Surg. 2021;141(7):1241-125.
131. Lavagnolo, U, Veronese, S, Negri, S, Magnan, B, and Sbarbati, A. Lipoaspirate processing for the treatment of knee osteoarthritis: a review of clinical evidences. Biomed Pharmacother. 2021;142:111997.
132. Muthu, S, Kartheek, RR, Jeyaraman, N, Rajendran, RL, Khanna, M, Jeyaraman, M, Packkyarathinam, RP, Gangadaran, P, et al. Is Culture Expansion Necessary in Autologous Mesenchymal Stromal Cell Therapy to Obtain Superior Results in the Management of Knee Osteoarthritis?-Meta-Analysis of Randomized Controlled Trials. Bioengineering (Basel). 2021;8(12).
133. Rodriguez-García, SC, Castellanos-Moreira, R, Uson, J, Naredo, E, O'Neill, TW, Doherty, M, Boesen, M, Pandit, H, et al. Efficacy and safety of intra-articular therapies in rheumatic and musculoskeletal diseases: an overview of systematic reviews. RMD Open. 2021;7(2).
134. Ude, CC, Shah, S, Ogueri, KS, Nair, LS, and Laurencin, CT. Stromal Vascular Fraction for Osteoarthritis of the Knee Regenerative Engineering. Regenerative Engineering and Translational Medicine. 2021.
135. Wei, ZJ, Wang, QQ, Cui, ZG, Inadera, H, Jiang, X, and Wu, CA. Which is the most effective one in knee osteoarthritis treatment from mesenchymal stem cells obtained from different sources? -A systematic review with conventional and network meta-analyses of randomized controlled trials. Ann Transl Med. 2021;9(6):452.
136. Álvarez Hernández, P, and de la Mata Llord, J. Expanded Mesenchymal Stromal Cells in Knee Osteoarthritis: A Systematic Literature Review. Reumatol Clin (Engl Ed). 2020.
137. Biazzo, A, D'Ambrosi, R, Masia, F, Izzo, V, and Verde, F. Autologous adipose stem cell therapy for knee osteoarthritis: where are we now? Phys Sportsmed. 2020;48(4):392-399.
138. Buzaboon, N, and Alshammary, S. Clinical applicability of adult human mesenchymal stem cell therapy in the treatment of knee osteoarthritis. Stem Cells and Cloning: Advances and Applications. 2020;13:117-136.
139. Migliorini, F, Berton, A, Salvatore, G, Candela, V, Khan, W, Longo, UG, and Denaro, V. Autologous Chondrocyte Implantation and Mesenchymal Stem Cells for the Treatments of Chondral Defects of the Knee- A Systematic Review. Curr Stem Cell Res Ther. 2020;15(6):547-556.
140. Kolasinski SL, Neogi T, Hochberg MC, et.al. American College of Rheumatology/Arthritis Foundation. 2019 American College of Rheumatology/Arthritis Foundation. Guideline for the Management of Osteoarthritis of the Hand, Hip and Knee. Arthritis Rheumatol. 2020 Feb;72(2):220-233. doi: 10.1002/art.41142. Epub 2020 Jan 6. Erratum in: Arthritis Rheumatol. 2021 May;73(5):79
141. American Academy of Orthopaedic Surgeons (AAOS). Clinical Practice Guideline for the Management of Glenohumeral Joint Osteoarthritis. Published March 23, 2020
142. Lee, JS, Shim, DW, Kang, KY, Chae, DS, and Lee, WS. Method Categorization of Stem Cell Therapy for Degenerative Osteoarthritis of the Knee: A Review. Int J Mol Sci. 2021;22(24).
143. Ding, W, Xu, YQ, Zhang, Y, Li, AX, Qiu, X, Wen, HJ, and Tan, HB. Efficacy and Safety of Intra-Articular Cell-Based Therapy for Osteoarthritis: Systematic Review and Network Meta-Analysis. Cartilage. 2021;13(1_suppl):104s-115s.
144. Gong, J, Fairley, J, Cicuttini, FM, Hussain, SM, Vashishtha, R, Chou, L, Wluka, AE, and Wang, Y. Effect of Stem Cell Injections on Osteoarthritis-related Structural Outcomes: A Systematic Review. J Rheumatol. 2021;48(4):585-597.
145. Chen, CF, Hu, CC, Wu, CT, Wu, HH, Chang, CS, Hung, YP, Tsai, CC, and Chang, Y. Treatment of knee osteoarthritis with intra-articular injection of allogeneic adipose-derived stem cells (ADSCs)

ELIXCYTE®: a phase I/II, randomized, active-control, single-blind, multiple-center clinical trial. Stem Cell Res Ther. 2021;12(1):562.
146. Lim, HC, Park, YB, Ha, CW, Cole, BJ, Lee, BK, Jeong, HJ, Kim, MK, Bin, SI, et al. Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cell Implantation Versus Microfracture for Large, Full-Thickness Cartilage Defects in Older Patients: A Multicenter Randomized Clinical Trial and Extended 5-Year Clinical Follow-up. Orthop J Sports Med. 2021;9(1):2325967120973052.
147. Lu, L, Dai, C, Du, H, Li, S, Ye, P, Zhang, L, Wang, X, Song, Y, et al. Intra-articular injections of allogeneic human adipose-derived mesenchymal progenitor cells in patients with symptomatic bilateral knee osteoarthritis: a Phase I pilot study. Regen Med. 2020;15(5):1625-1636.
148. Trebinjac, S, and Gharairi, M. Mesenchymal Stem Cells for Treatment of Tendon and Ligament Injuries-clinical Evidence. Med Arch. 2020;74(5):387-390.
149. American Association of Hip and Knee Surgeons (AAHKS) Position Statement on Biologics for Advanced Hip and Knee Arthritis. June 2019
150. Lamo-Espinosa JM, Mora G, Blanco JF, et al. Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: long-term follow up of a multicenter randomized controlled clinical trial (phase I/II). J Transl Med. Jul 31 2018; 16(1): 213. PMID 30064455
151. Lamo-Espinosa JM, Mora G, Blanco JF, et al. Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: multicenter randomized controlled clinical trial (phase I/II). J Transl Med. Aug 26, 2016; 14(1): 246. PMID 27565858
152. Maheshwer B, Polce EM, Paul K, et al. Regenerative Potential of Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis and Chondral Defects: A Systematic Review and Meta-analysis. Arthroscopy. Jan 2021; 37(1): 362-378. PMID 32497658
153. Kim SH, Djaja YP, Park YB, et al. Intra-articular Injection of Culture-Expanded Mesenchymal Stem Cells Without Adjuvant Surgery in Knee Osteoarthritis: A Systematic Review and Meta-analysis. Am J Sports Med. Sep 2020; 48(11): 2839-2849. PMID 31874044
154. Hayes, Inc. Health Technology Assessment Autologous Microfragmented Adipose Tissue Injection for Treatment of Osteoarthritis February 28, 2022
155. Kim SH, Djaja YP, Park YB, et al. Intra-articular Injection of Culture-Expanded Mesenchymal Stem Cells Without Adjuvant Surgery in Knee Osteoarthritis: A Systematic Review and Meta-analysis. Am J Sports Med. Sep 2020; 48(11): 2839-2849. PMID 31874044
156. Jin L, Yang G, Men X, et al. Intra-articular Injection of Mesenchymal Stem Cells After High Tibial Osteotomy: A Systematic Review and Meta-analysis. Orthop J Sports Med. Nov 2022; 10(11): 23259671221133784. PMID 36452339
157. Zaffagnini S, Andriolo L, Boffa A, et al. Microfragmented Adipose Tissue Versus Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis: A Prospective Randomized Controlled Trial at 2-Year Follow-up. Am J Sports Med. Sep 2022; 50(11): 2881-2892. PMID 35984721
158. Mautner K, Gottschalk M, Boden SD, et al. Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med. Nov 02 2023. PMID 37919438
159. Kim KI, Lee MC, Lee JH, et al. Clinical Efficacy and Safety of the Intra-articular Injection of Autologous Adipose-Derived Mesenchymal Stem Cells for Knee Osteoarthritis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial. Am J Sports Med. Jul 2023; 51(9): 2243-2253. PMID 37345256
160. Xiao Z, Wang X, Li C, et al. Effects of the umbilical cord mesenchymal stem cells in the treatment of knee osteoarthritis: A systematic review and meta-analysis. Medicine (Baltimore). Nov 15 2024; 103(46): e40490. PMID 39560593
161. Giorgino R, Alessandri Bonetti M, Migliorini F, et al. Management of hip osteoarthritis: harnessing the potential of mesenchymal stem cells-a systematic review. Eur J Orthop Surg Traumatol. Dec 2024; 34(8): 3847-3857. PMID 39254726

162. American Academy of Orthopaedic Surgeons. Management of Osteoarthritis of the Hip. https://www.aaos.org/globalassets/quality-and-practice-resources/osteoarthritis-of-the-hip/oah-cpg.pdf. Updated December 1, 2023
163. UpToDate. Investigational approaches to the management of osteoarthritis. Topic last updated February 2025. Also available at https://www.uptodate.com
164. UpToDate. Biologic Therapies for Tendon and Muscle Injury. Topic last updated December 2024. Also available at https://www.uptodate.com
165. Hayes Inc. Health Technology Assessment Adipose Derived Stem Cell Therapy for Knee Osteoarthritis. March 2024
166. Hayes Inc. Health Technology Assessment Autologous Stem Cell Therapy for Treatment of Avascular Necrosis of Hip. December 2019
167. Hayes Inc. Health Technology Assessment. Autologous Bone Marrow Derived Mesenchymal Stem Cell Therapy for Treatment of Nonunion of the Lower Extremity. October 2016
168. Hayes Inc. Health Technology Assessment Bone Marrow-Derived Stem Cell Therapy for Knee Osteoarthritis. March 2024
169. Randy R, Yosua K, Guntara A et. al. Stem cells therapy as a treatment for discogenic low back pain: A systematic review. Int J Spine Surg published online 8 January 2025 https://www/ijssurgery.com/content/early/eary/2025/01/07/86717

CODES

To report provider services, use appropriate CPT codes, HCPCS codes, Revenue codes, and/or ICD diagnosis codes.

Codes	Number	Description
CPT		
	20999	Unlisted procedure, musculoskeletal system, general
	27599	Unlisted procedure, femur or knee (may be utilized for Lipogems)
	38205	Blood derived hematopoietic progenitor cell harvesting for transplantation, per collection allogeneic
	38206	Blood derived hematopoietic progenitor cell harvesting for transplantation autologous
	38212	Transplant preparation of hematopoietic progenitor cells; red blood cell removal
	38215	Transplant preparation of hematopoietic progenitor cells; cell concentration in plasma, mononuclear or buffy coat layer
	38230	Bone marrow harvesting for transplantation allogeneic
	38232	Bone marrow harvesting for transplantation autologous

Codes	Number	Description
	38240	Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor
	38241	Hematopoietic progenitor cell (HPC); autologous transplantation
	0232T	Injection(s), platelet-rich plasma, any tissue, including image guidance, harvesting and preparation when performed
	0263T	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; complete procedure including unilateral or bilateral bone marrow harvest
	0264T	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; complete procedure excluding bone marrow harvest
	0265T	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; unilateral or bilateral bone marrow harvest only for intramuscular autologous bone marrow cell therapy
	0565T	Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; tissue harvesting and cellular implant creation
	0566T	Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; injection of cellular implant into knee joint including ultrasound guidance, unilateral
	0717T	Autologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tear; adipose tissue harvesting, isolation and preparation of harvested cells. Including incubation with cell dissociation enzymes, filtration, washing and concentration of ADRCs
	0718T	Autologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tear; injection into supraspinatus tendon including ultrasound guidance, unilateral
HCPCS		
	None	
Type of Service	Surgery	
Place of Service	Inpatient/Outpatient	

POLICY HISTORY

Date	Action	Action
March 2025	Annual Review	Policy Revised
March 2023	Annual Review	Policy Revised
March 2022	Annual Review	Policy Revised
February 2022	Annual Review	Policy Revised
February 2021	Annual Review	Policy Revised
February 2020	Annual Review	Policy Revised
February 2019	Annual Review	Policy Renewed
August 2018	Interim Review	Policy Revised
February 2018	Annual Review	Policy Revised
April 2017	Annual Review	Policy Revised
April 2016	Annual Review	Policy Renewed
May 2015	Annual Review	Policy Revised
March 2015	Interim Review	Policy Revised
June 2014	Annual Review	New Policy

New information or technology that would be relevant for Wellmark to consider when this policy is next reviewed may be submitted to:

Wellmark Blue Cross and Blue Shield
Medical Policy Analyst
PO Box 9232
Des Moines, IA 50306-9232

*CPT® is a registered trademark of the American Medical Association.